Pembrolizumab,MK-4830,Belzutifan,Lenvatinib,Quavonlimab,Favezelimab
Eisai,Merck
['lenva', 'belzutifan']
at a median follow-up of 6.9 months, a regimen combining the hif-2 inhibitor belzutifan and the vegf-tki lenvatinib elicited an orr of 50% (95% ci, 29-71) among 24 patients who had received at least 2 postbaseline scans. #kicsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.